This randomized trial assesses the effect of oral nicotinamide riboside treatment for 52 weeks vs placebo on clinical outcomes among patients with early Parkinson disease.
This randomized trial assesses the effect of oral nicotinamide riboside treatment for 52 weeks vs placebo on clinical outcomes among patients with early Parkinson disease.